- The US FDA has issued a warning letter dated 18 November 2026 for Alkem Laboratories' manufacturing plant at Amaliya, Daman.
- It follows an FDA inspection of the plant from 20 April to 1 May 2026, which the FDA had classified as Official Action Indicated (OAI).
- Alkem says it will respond within the set timeline and continues to make and supply approved products from the plant to the US. It sees no material impact on current operations.
What it means for Alkem's business
US supply from the plant continues
- Alkem says it continues to make and supply approved products from the Daman plant to the US market.
- It says there is no material impact on its current operations, finances or other activities.
Work to fix the issues
- The letter requires Alkem to put corrective and preventive actions in place for the FDA's observations and to stop them recurring.
- That takes management time and spending. The filing gives no cost.
New US approvals from the plant may wait
- While a warning letter is open, the FDA can hold back approval of new products made at the plant. The filing does not say whether any of Alkem's pending approvals depend on this plant.
What the filing says
The warning letter
- Issued by: the US Food and Drug Administration (USFDA).
- Dated 18 November 2026. Alkem informed the exchanges on 19 November 2026.
- Plant: Alkem's manufacturing facility at Amaliya, Daman.
Background
- The FDA inspected the plant from 20 April to 1 May 2026 and classified the inspection as Official Action Indicated (OAI).
- Alkem reported the inspection in earlier filings dated 2 May and 6 August 2026.
What the letter asks for
- It relates to observations made during the inspection, and requires Alkem to implement corrective and preventive actions and prevent recurrence.
- Alkem says it will respond to the FDA within the stipulated timeline.
Impact stated by Alkem
- No material impact on current operations, financial or other activities.
Why it matters
What a warning letter is
- A US FDA warning letter is a formal notice that a plant did not meet the FDA's manufacturing standards. It often follows an OAI inspection.
- It stays open until the FDA is satisfied that the problems have been fixed.
What OAI means
- Official Action Indicated is the most serious of the FDA's three inspection outcomes. It means the FDA found problems that call for regulatory action.
What the filing does not say
- It does not say how much of Alkem's US sales come from the Daman plant, which products it makes, or how many observations the letter covers.
What to watch next
- Alkem's response to the FDA, any re-inspection of the plant, and comments on it in Alkem's next quarterly results.
Funds that hold Alkem
- DSP Value Fund2.5% of the fund
- HDFC Mid Cap Fund1.9% of the fund
- SBI Large & Midcap Fund1.9% of the fund
- DSP Midcap Fund1.8% of the fund
- DSP Flexi Cap Fund1.6% of the fund
- HDFC Multi Cap Fund1.5% of the fund
- Sundaram Mid Cap Fund1.4% of the fund
- Axis Midcap Fund1.4% of the fund
- Nippon India Growth Mid Cap Fund1.3% of the fund
- HDFC ELSS Tax Saver Fund1.2% of the fund
and 8 more
From each fund house's October 2026 portfolio.
Source: Exchange filings
Alkem: questions
Why did Alkem get a US FDA warning letter?
It follows an FDA inspection of Alkem's Amaliya, Daman plant from 20 April to 1 May 2026, classified as Official Action Indicated. The letter, dated 18 November 2026, asks Alkem to correct the FDA's observations.
What does the warning letter mean for Alkem's business?
Alkem says it keeps making and supplying approved products from the plant to the US and sees no material impact on current operations. It now has to put corrective actions in place, and new US product approvals from the plant may wait until the FDA is satisfied.
Is Alkem still supplying the US from the Daman plant?
Yes. Alkem says it continues to manufacture and supply approved products from the plant to the US market.
What happens next for Alkem's Daman plant?
Alkem will respond to the FDA within the stipulated timeline and implement corrective and preventive actions for the FDA's observations.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.


